Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.62), $0.03 better than the analyst estimate of ($1.65). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.15 million.

“In 2019 we created a substantial foundation based on the strong launch of Crysvita and the validation of our gene therapy platform across multiple clinical programs,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “In 2020, we anticipate building on this momentum as we look to the potential approvals of UX007 for LC-FAOD and Crysvita for TIO. We also expect to advance our gene therapy programs into pivotal studies and bring two new programs into the clinic while continuing to exercise financial discipline.”

2020 Guidance

Crysvita Guidance in Ultragenyx TerritoriesIn 2020, the company continues to expect Crysvita revenue in the Ultragenyx territories to be between $125 million and $140 million, which excludes the European territory revenue. Ultragenyx territories include the collaboration revenue from the North American profit share territory (US and Canada) and other regions where revenue from product sales are recognized by Ultragenyx (Latin America, Turkey). In December 2019, the European territory royalty revenue rights were sold to Royalty Pharma. As a result, the company will no longer receive cash payments from the EU territory royalty revenue rights beginning January 1, 2020, until the respective threshold amount is met; however, the company will continue to record the royalty as “non-cash” revenue.

2020 Expected Net Cash Burn RateThe company also expects a more than 20 percent reduction in net cash burn (net cash used in operations plus capital expenditures) in 2020 compared to 2019 due to a combination of financial discipline in spending with flattening operating expense growth, combined with the significantly larger growth in revenue.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• First American Financial (FAF) Misses Q1 EPS by 19c
• First Mid Bancshares, Inc. (FMBH) Tops Q1 EPS by 8c